Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study

Table 3

HR of recurrent CVD by keep or stop using acarbose.

Risk factor	Recurrence of CVD	No recurrence of CVD	Crude				Adjusted
			HR	95% CI		𝑃	HR	95% CI		𝑃
				Low	Up			Low	Up
Stop acarbose users	627	2242	Ref.	—	—		Ref.	—	—	—
Keep acarbose users	582	1174	0.84	0.752	0.944	0.003	0.88	0.781	0.987	0.029
Cumulative duration of therapy (months)
<12	508	1142	0.98	0.87	1.1	0.715	1.00	0.891	1.132	0.947
12–24	49	18	0.52	0.392	0.702	<0.001	0.48	0.355	0.645	<0.001
>24	25	14	0.29	0.196	0.441	<0.001	0.38	0.249	0.567	<0.001
Cumulative dose (mg)
1–10500	523	1149	0.95	0.848	1.07	0.413	0.97	0.86	1.091	0.600
10501–28000	39	16	0.45	0.324	0.621	<0.001	0.47	0.338	0.657	<0.001
>28000	20	9	0.33	0.211	0.518	<0.001	0.40	0.253	0.628	<0.001

Adjusted age, gender, other diabetic medications, and CCI. CVD: cardiovascular disease.